Annual report
150A.TEDINET S100TPOV
Period2023-04-01 → 2024-03-31
Filed2024-06-25
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed
Key figures · 74
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥3.5bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥3.0bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥2.3bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥1.5bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥723m | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥208m | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥165m | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥195m | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥161m | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥83m | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥143m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥93m | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥195m | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥161m | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥145m | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥188m | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥61m | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥142m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥526m | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥2.5bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥2.0bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥1.6bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥881m | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥836m | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥705m | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥661m | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.8bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥1.3bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥663m | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥84m | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥176m | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.2bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥803m | at 2023-03-31 | Standalone | Cash and deposits |
| Cash & equivalents | ¥1.2bn | at 2024-03-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥803m | at 2023-03-31 | Standalone | Cash and cash equivalents |
| Cash & equivalents | ¥680m | at 2022-03-31d | Standalone | Cash and cash equivalents |
| Operating cash flow | ¥300m | 2023-04-01 → 2024-03-31 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | ¥225m | 2022-04-01 → 2023-03-31 | Standalone | Net cash provided by used in operating activities |
| Operating cash flow | ¥145m | 2021-04-01 → 2022-03-31d | Standalone | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥117m | 2023-04-01 → 2024-03-31 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | −¥195m | 2022-04-01 → 2023-03-31 | Standalone | Net cash provided by used in investment activities |
| Investing cash flow | −¥176m | 2021-04-01 → 2022-03-31d | Standalone | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥211m | 2023-04-01 → 2024-03-31 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥94m | 2022-04-01 → 2023-03-31 | Standalone | Net cash provided by used in financing activities |
| Financing cash flow | ¥486m | 2021-04-01 → 2022-03-31d | Standalone | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥31.29 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥41.25 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥15.33 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-7,203.3 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-26,770.92 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥31.27 | 2023-04-01 → 2024-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥334.63 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥-258.78 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥-352.71 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥-70,217.77 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥-62,409.83 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 72.2% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.9% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 42.2% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 9.5% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 21.1% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 9.2% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 18.8% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 16.3% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 5,482,600 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 10,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 10,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 10,200 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 10,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 427 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 383 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 301 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 216 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 201 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 46
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥272,000 |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥7m |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥1.3bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥433m |
| Home Care Medicine Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥2m |
| Home Care Medicine Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥2m |
| Home Care Medicine Businessreportable segment | employees | at 2024-03-31 | 183 pure |
| Home Care Medicine Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥1.4bn |
| Home Care Medicine Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥1.4bn |
| Home Care Medicine Businessreportable segment | segment assets | at 2024-03-31 | ¥305m |
| Home Care Medicine Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥178m |
| Regional Revitalization Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥140m |
| Regional Revitalization Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥94m |
| Regional Revitalization Businessreportable segment | employees | at 2024-03-31 | 218 pure |
| Regional Revitalization Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥2.1bn |
| Regional Revitalization Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥2.1bn |
| Regional Revitalization Businessreportable segment | segment assets | at 2024-03-31 | ¥934m |
| Regional Revitalization Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥464m |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥142m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥96m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥3.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥3.5bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥1.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥642m |
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥5m |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥7m |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥913m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥390m |
| Home Care Medicine Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥3m |
| Home Care Medicine Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥1m |
| Home Care Medicine Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥1.4bn |
| Home Care Medicine Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥1.4bn |
| Home Care Medicine Businessreportable segment | segment assets | at 2023-03-31 | ¥287m |
| Home Care Medicine Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥218m |
| Regional Revitalization Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥266m |
| Regional Revitalization Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥79m |
| Regional Revitalization Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥1.6bn |
| Regional Revitalization Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥1.6bn |
| Regional Revitalization Businessreportable segment | segment assets | at 2023-03-31 | ¥794m |
| Regional Revitalization Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥337m |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-04-01 → 2023-03-31 | ¥269m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥80m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥3.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥3.0bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥1.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥555m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 977
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report non consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)有限責任 あずさ監査法人 | |
| Cpa1 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)福島 康生 | |
| Cpa2 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)三宅 潔 | |
| Key audit matters non consolidated (text) | FilingDateInstant | Text · Plus | |
| Overview kam non consolidated (text) | FilingDateInstant | Text · Plus | |
| Short description kam non consolidated | FilingDateInstant_Row1Member | Original text (Japanese)在宅医療サービス及び障がい者雇用支援サービスに係る売上高の正確性及び期間帰属の適切性 | |
| Description including reason kam non consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Reference kam non consolidated | FilingDateInstant_Row1Member | Original text (Japanese)財務諸表注記「（収益認識関係）1．顧客との契約から生じる収益を分解した情報」 | |
| Reference2 kam non consolidated | FilingDateInstant_Row1Member | Original text (Japanese)財務諸表注記「(重要な会計方針)５．収益及び費用の計上基準」 | |
| Auditors response kam non consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Other information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Fee related information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Number of submission | FilingDateInstant | 1 | |
| Net sales (5-year summary) | Prior4YearDuration_NonConsolidatedMember | 723335000 | JPY |
| Net sales (5-year summary) | Prior3YearDuration_NonConsolidatedMember | 1502804000 | JPY |
| Net sales (5-year summary) | Prior2YearDuration_NonConsolidatedMember | 2330183000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration_NonConsolidatedMember | 2967671000 | JPY |
| Net sales (5-year summary) | CurrentYearDuration_NonConsolidatedMember | 3482000000 | JPY |
| Ordinary income loss (5-year summary) | Prior4YearDuration_NonConsolidatedMember | -93040000 | JPY |
| Ordinary income loss (5-year summary) | Prior3YearDuration_NonConsolidatedMember | -142541000 | JPY |
| Ordinary income loss (5-year summary) | Prior2YearDuration_NonConsolidatedMember | 82701000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration_NonConsolidatedMember | 160762000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYearDuration_NonConsolidatedMember | 194798000 | JPY |
| Net income loss (5-year summary) | Prior4YearDuration_NonConsolidatedMember | -525513000 | JPY |
| Net income loss (5-year summary) | Prior3YearDuration_NonConsolidatedMember | -142122000 | JPY |
| Net income loss (5-year summary) | Prior2YearDuration_NonConsolidatedMember | 60801000 | JPY |
| Net income loss (5-year summary) | Prior1YearDuration_NonConsolidatedMember | 187858000 | JPY |
| Net income loss (5-year summary) | CurrentYearDuration_NonConsolidatedMember | 145449000 | JPY |
| Equity in earnings losses of affiliates if equity method is applied (5-year summary) | Prior4YearDuration_NonConsolidatedMember | － | JPY |
| Equity in earnings losses of affiliates if equity method is applied (5-year summary) | Prior3YearDuration_NonConsolidatedMember | － | JPY |
| Equity in earnings losses of affiliates if equity method is applied (5-year summary) | Prior2YearDuration_NonConsolidatedMember | － | JPY |
| Equity in earnings losses of affiliates if equity method is applied (5-year summary) | Prior1YearDuration_NonConsolidatedMember | － | JPY |
| Equity in earnings losses of affiliates if equity method is applied (5-year summary) | CurrentYearDuration_NonConsolidatedMember | － | JPY |
| Capital stock (5-year summary) | Prior4YearInstant_NonConsolidatedMember | 460125000 | JPY |
| Capital stock (5-year summary) | Prior3YearInstant_NonConsolidatedMember | 485125000 | JPY |
| Capital stock (5-year summary) | Prior2YearInstant_NonConsolidatedMember | 744325000 | JPY |
| Capital stock (5-year summary) | Prior1YearInstant_NonConsolidatedMember | 985075000 | JPY |
| Capital stock (5-year summary) | CurrentYearInstant_NonConsolidatedMember | 1163371000 | JPY |
| Total number of issued shares (5-year summary) | Prior4YearInstant_NonConsolidatedMember | 10000 | |
| Total number of issued shares (5-year summary) | Prior3YearInstant_NonConsolidatedMember | 10200 | |
| Total number of issued shares (5-year summary) | Prior2YearInstant_NonConsolidatedMember | 10000 | |
| Total number of issued shares (5-year summary) | Prior1YearInstant_NonConsolidatedMember | 10000 | |
| Total number of issued shares (5-year summary) | CurrentYearInstant_NonConsolidatedMember | 5482600 | |
| Total number of issued shares class a preferred shares (key data) | Prior4YearInstant_NonConsolidatedMember | 6100 | |
| Total number of issued shares class a preferred shares (key data) | Prior3YearInstant_NonConsolidatedMember | 6100 | |
| Total number of issued shares class a preferred shares (key data) | Prior2YearInstant_NonConsolidatedMember | 6100 | |
| Total number of issued shares class a preferred shares (key data) | Prior1YearInstant_NonConsolidatedMember | 6100 | |
| Total number of issued shares class a preferred shares (key data) | CurrentYearInstant_NonConsolidatedMember | － | |
| Total number of issued shares class b preferred shares (key data) | Prior4YearInstant_NonConsolidatedMember | 3530 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 13 of 13 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |